혜화의학회지 (Journal of Haehwa Medicine)

  • 제21권1호
  • /
  • Pages.11-21
  • /
  • 2012
  • /
  • 2586-3002(pISSN)
  • /
  • 2586-3347(eISSN)
대전대학교 한의학연구소 (Research Institute of Korean Medicine)
권호 표지

면역억제제에 의한 당뇨 관련 유전자의 DNA microarray 분석

DNA Microarrays Analysis of Gene Expression Profiles in Diabetes-related genes using Immunosuppressant

  • Kim, Kyoung-Shin (Dept. of Pathology, College of Oriental Medicine, Daejeon University) ;
  • Kim, Byoung-Soo (Dept. of Pathology, College of Oriental Medicine, Daejeon University)
  • 투고 : 2012.06.11
  • 심사 : 2012.06.27
  • 발행 : 2012.08.20
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

New onset diabetes is a major complication after kidney transplantation. However, the natural course of posttransplantation diabetes mellitus (PTDM) remains unclear. The aim of this study was to demonstrate the detailed natural courses of PTDM according to the onset and persistency of hyperglycemia, and to investigate risk factors for development of different courses of PTDM in renal allograft recipients. The purpose of this study is to develop novel immune suppressants for PTDM using of action mechanism of them. The use of immunosuppressive drugs in transplanted patients is associated with the development of diabetes, possibly due to ${\beta}$-cell toxicity. To better understand the mechanisms leading to post-transplant diabetes, we investigated the actions of prolonged exposure of ${\beta}$-cells to therapeutical levels of tacrolimus (FK506) or cyclosporin A(CsA). The immunosuppressive drug cyclosporine(CsA) is a potent agent widely used after organ transplantations and various autoimmune disorders. After using CsA, some patients suffer severe complications including renal and vascular toxicity. The renal or vascular toxicity is influenced by the degree of the endothelial damage. FK506(tacrolimus) is a widely used immunosuppressive agent in the treatment of various medical conditions, including autoimmune disease, bone marrow and organ transplantations. We found some interesting clusters and confirmed the feasibility of cDNA microarray in the study of Immunosuppressant. In this study, we investigated gene expression patterns induced by Immunosuppressant in RIN-m5F of rat insulinoma cell line. Gene expressions evaluated using cDNA microarry in two clusters were increased or decreased. this study provides comprehensive comparison of the patterns of gene expression changes induced by CsA and FK506 in ${\beta}$-cells. This study could establish that the mode of action mechanism by which currently used insulin inhibitors inducing PTDM could be elucidated at least in part, which raises the possibility that novel immune suppressive PTDM can be developed. The molecular biological study on PTDM will also contribute the progress in diabetes research field as well as in that of PTDM.

키워드

참고문헌

  1. Pharmacodynamics of immunosuppressive drusgs-Current opinion in Immunology vol. 12, pp. 557-562, 2000. https://doi.org/10.1016/S0952-7915(00)00138-2
  2. 김정미.김동한.김태우.조규향.최준혁.박종원.도준영.윤경우. 이식 후 12개월이 지난 신이식 환자에서 Cyclosporine Trough Level과 2-hour Postdose Blood Level 사이의 상관 관계 및 적정 C2 Level. 대한신장학회지, 21(3):435-442, 2002.
  3. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA, 95(25):14863-8, 1998. https://doi.org/10.1073/pnas.95.25.14863
  4. First MR. Tacrolimus based immunosuppression. J Nephrol. 17:S25-31, 2004.
  5. 강종명. 새로운 면역억제제의 임상적 응용. 대한신장학회지, 제18권 부록1호, pp100-111, 1999.
  6. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66:807-15, 1991. https://doi.org/10.1016/0092-8674(91)90124-H
  7. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signaling enzyme in T-lymphocyte activation. Nature 357:695-7, 1992. https://doi.org/10.1038/357695a0
  8. O'Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O'Neill EA. FK-506 and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 357:692-4, 1992. https://doi.org/10.1038/357692a0
  9. Michael C. Lawrence, Harshika S. Bhatt, Jeannette M. Watterson, And Richard A. Easom: Regulation of Insulin Gene Transcription by a Ca2+ Responsive Pathway Involving Calcineurin and Nuclear Factor of Activated T Cells. Molecular Endocrinology 15(10):1758-1767, 2001. https://doi.org/10.1210/mend.15.10.0702
  10. Wang H, Maechler P, Hagenfeldt KA, Wollheim CB: Dominant-negative suppression of HNF-1alpha function results in defective insulin gene transcription and impaired metabolism-secretion coupling in a pancreatic beta-cell line. EMBO J 17:6701-6713, 1998. https://doi.org/10.1093/emboj/17.22.6701
  11. Heit JJ: Calcineurin/NFAT signaling in the beta-cell: From diabetes to new therapeutics. Bioessays. Oct;29(10):1011-21, 2007. https://doi.org/10.1002/bies.20644
  12. Thomas R, Gerlinde W, Henrike W, Norbert T, Jens L, Thomas E, et al. CYP2D6 genotype: Impact on adverse effects and nonresponse during treatment with antidepressant-A pilot study. Clin Pharmacol Ther 75:386-393, 2004. https://doi.org/10.1016/j.clpt.2003.12.015
  13. Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics. Clin Pharmacokinet 41:453-470, 2002. https://doi.org/10.2165/00003088-200241070-00001
  14. Budde K, Fritsche L, Mai I, Neumayer HH et al : Clinical pharmacok inetics of tacrolimus the rapyafter renal transplantation. Int J Clin P harmacol Ther 34:493-497, 1996
  15. Coto E, Tavira B. Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 88(3S):62-7, 2009. https://doi.org/10.1097/TP.0b013e3181aa7d04
  16. Dumont RJ, Ensom MH : Methods for clinical monitoring of cyclosporine in transplant patients. Clin Pharmacokinet 38:427-447, 2000. https://doi.org/10.2165/00003088-200038050-00004
  17. 황진순. MODY 증후군. 대한소아내분비학회지, 15(1):1-6, 2010.
  18. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3:178-185, 2003 https://doi.org/10.1034/j.1600-6143.2003.00010.x
  19. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J: A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 73:775-782, 2002. https://doi.org/10.1097/00007890-200203150-00021
  20. Uchizono Y, Iwase M, Nakamura U, Sasaki N, Goto D, Iida M: Tacrolimus impairment of insulin secretion in isolated rat islets occurs at multiple distal sites in stimulus-secretion coupling. Endocrinology 145:2264-2272, 2004. https://doi.org/10.1210/en.2003-1152
  21. Cho YM, Park KS, Jung HS, Jeon HJ, Ahn C, Ha J, Kim SJ, Rhee BD, Kim SY, Lee HK: High incidence of tacrolimus-associated posttransplantation diabetes in the Korean renal allograft recipients according to American Diabetes Association criteria. Diabetes Care 26:1123-1128, 2003. https://doi.org/10.2337/diacare.26.4.1123
  22. Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez Rocafort L, Haider S, Woodworth TG, Brennan DC. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 3:590-8, 2003. https://doi.org/10.1034/j.1600-6143.2003.00082.x
  23. 이식 후 당뇨병의 발생과 그 임상적 의의. 강진모, 하종원, 박양진, 박경수, 김상준. J Korean Soc Transplant 21:262-268, 2007.
  24. Kang WH, Kim SM, Ju MK, Chang HK, Ahn HJ, Kim SI, Kim YS. Risk factors of post-transplantation diabetes mellitus in renal transplant recipients. J Korean Soc Transplant, 21:1111-8 2007.
  25. Sato T, Inagaki A, Uchida K, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Tominaga Y, Okajima Y, Ohta K, Suga H, Taguchi S, Kakiya S, Itatsu T, Kobayashi T, Nakao A. Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. Transplantation 76:1320-6, 2003. https://doi.org/10.1097/01.TP.0000084295.67371.11
  26. Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 13:221-7, 2002.
  27. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 65:515-23, 1998. https://doi.org/10.1097/00007890-199802270-00011
  28. Tamura K, Fujimura T, Tsutsumi T, Nakamura K, Ogawa T, Atumaru C, Kobayashi M. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation 59:1606-13, 1995. https://doi.org/10.1097/00007890-199506000-00018
  29. Han Cho, James Mu, Jason K. Kim, Joanne L. Thorvaldsen, Gerald I. Shulman and Morris J. Birnbaum. Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 ($PKB{\beta}$). Science., 292(5522):1728-1731. 2001. https://doi.org/10.1126/science.292.5522.1728
  30. Guengerich FP. Cytochromes P450, drugs and diseases. MolInterv. 3(4):194-204, 2003.
  31. Smith G, Wolf CR, Deeni YY, Dawe RS, Evans AT, Comrie MM, Ferguson J, and Ibbotson SH. Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet 361:1336-1343, 2003. https://doi.org/10.1016/S0140-6736(03)13081-4